<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00878540</url>
  </required_header>
  <id_info>
    <org_study_id>L2/2008</org_study_id>
    <secondary_id>EudraCT-Nr.: 2008-002704-26</secondary_id>
    <nct_id>NCT00878540</nct_id>
  </id_info>
  <brief_title>Short-term Metabolic Effects of Mirtazapine in Healthy Subjects</brief_title>
  <acronym>SMMS</acronym>
  <official_title>Phase 1 Study of Mirtazapine in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Max-Planck-Institute of Psychiatry</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Max-Planck-Institute of Psychiatry</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine metabolic changes upon a 7 day medication of 30 mg&#xD;
      mirtazapine per day in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic changes upon a 7 day medication of 30 mg mirtazapine per day</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>mirtazapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mirtazapine</intervention_name>
    <description>30 mg mirtazapine once daily for 7 days</description>
    <arm_group_label>mirtazapine</arm_group_label>
    <other_name>Remergil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male sex&#xD;
&#xD;
          -  Age 20-25 years&#xD;
&#xD;
          -  Somatically and mentally healthy&#xD;
&#xD;
          -  Normal body weight (body mass index (BMI)18.5-25)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoking within the last 6 months&#xD;
&#xD;
          -  Medication within last 6 months&#xD;
&#xD;
          -  Current or former psychiatric illness&#xD;
&#xD;
          -  Positive family history (first grade relatives) for metabolic diseases&#xD;
&#xD;
          -  Alcohol abuse&#xD;
&#xD;
          -  Current or former illicit drug abuse&#xD;
&#xD;
          -  Current or former drug abuse&#xD;
&#xD;
          -  Known intolerance to, or former prescription of study medication&#xD;
&#xD;
          -  Participation in other clinical trials at the same time or participation in clinical&#xD;
             trials associated with administration of a drug within the last 6 months&#xD;
&#xD;
          -  Homelessness&#xD;
&#xD;
          -  Shift work within last 12 months&#xD;
&#xD;
          -  Known hypersensitivity to mirtazapine or other components of the drug given&#xD;
&#xD;
          -  Known epilepsy; glaucoma; liver, kidney, or heart disease; urinary dysfunction;&#xD;
             hypotonia; diabetes or any other metabolic disease&#xD;
&#xD;
          -  Known hematologic disease, especially agranulocytosis or leukopenia&#xD;
&#xD;
          -  Blood donation within last 6 months prior to the begin of the study&#xD;
&#xD;
          -  Hemoglobin below 13.5 mg/dL&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florian Holsboer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Max Planck Institute of Psychiatry, Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Max Planck Institue of Psychiatry</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>April 8, 2009</study_first_submitted>
  <study_first_submitted_qc>April 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2009</study_first_posted>
  <last_update_submitted>September 15, 2010</last_update_submitted>
  <last_update_submitted_qc>September 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Florian Holsboer</name_title>
    <organization>Max-Planck-Institute of Psychiatry</organization>
  </responsible_party>
  <keyword>mirtazapine</keyword>
  <keyword>metabolism</keyword>
  <keyword>depression</keyword>
  <keyword>Healthy males</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirtazapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

